Companies/US/ASND

ASCENDIS PHARMA A/S

Income flow

Annual
ASND 20-F Income StatementPeriod 2025-12-31Source 20-F
United StatesEUR 546MEuropeEUR 121MRest Of WorldEUR 53MDKEUR 13MRevenueEUR 720M+98% Y/YGross profitEUR 625M+96% Y/YCost of revenueEUR 95M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 20-F · EUR
By geography
By geographyEUR 733M
  • United StatesEUR 546M74.5%
  • EuropeEUR 121M16.5%
  • Rest Of WorldEUR 53M7.2%
  • DKEUR 13M1.8%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).65.8MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).65.6M